At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 244 enrolled
Drug / intervention
AZD3355drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Double-blind, Placebo Controlled, Phase IIA Study to Assess the Effect on Gastroesophageal Reflux Disease (GERD) Symptoms, Pharmacokinetics, Safety and Tolerability of 4 Weeks Treatment With AZD3355 65 mg Bid as add-on Treatment to a Proton Pump Inhibitor (PPI) in Patients With an Incomplete Response to PPI.
In Brief
A Phase 2 clinical trial evaluating AZD3355 for Gastroesophageal Reflux Disease (GERD). Completed, enrolled 244 participants across 38 sites in 8 countries.
Detailed Summary
The purpose of this study is to estimate the effect of AZD3355 as an add-on treatment to a Proton Pump Inhibitor (PPI) on Gastroesophageal reflux disease (GERD) symptoms in patients with an incomplete response to PPI treatment.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsGastroesophageal Reflux Disease (GERD)
CountriesAustralia, Belgium, France, Germany, Hungary, Netherlands, Norway, Romania
Collaborators--
Timeline
Phase 2CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedNov 2006
Enrollment StartNov 2006
Primary CompletionJun 2007
TodayJul 2026
First PostedNov 1, 2006
Enrollment StartNov 1, 2006
Primary CompletionJun 1, 2007
TodayJul 2, 2026
Enrollment to primary: 7 monthsPosted 19.7 years ago
Interventions
AZD3355drug